A U.S. district court found key claims of a Scale Biosciences patent invalid for failing written‑description and enablement requirements in a lawsuit where Parse Biosciences is the defendant. The ruling undermines one of the patents asserted by Scale (now owned by 10x Genomics) against Parse and could alter competitive positioning in instrument‑free single‑cell library preparation. The decision follows other disputes in the single‑cell space and may affect ongoing litigation and licensing negotiations. Companies using split‑pool barcoding and similar approaches will watch subsequent appeal or PTAB actions for precedent on patent scope in single‑cell technologies.